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Graphene oxide sheets and quantum dots inhibit
α-synuclein amyloid formation by different
mechanisms†
Marziyeh Ghaeidamini, David Bernson, * Nima Sasanian, Ranjeet Kumar and
Elin K. Esbjörner *
Aggregation and amyloid formation of the 140-residue presynaptic and intrinsically disordered protein
α-synuclein (α-syn) is a pathological hallmark of Parkinson’s disease (PD). Understanding how α-syn forms
amyloid fibrils, and investigations of agents that can prevent their formation is therefore important. We
demonstrate herein that two types of graphene oxide nanoparticles (sheets and quantum dots) inhibit
α-syn amyloid formation by different mechanisms mediated via differential interactions with both mono-
mers and fibrils. We have used thioflavin-T fluorescence assays and kinetic analysis, circular dichroism,
dynamic light scattering, fluorescence spectroscopy and atomic force microscopy to asses the kinetic
nature and efficiency of this inhibitory effect. We show that the two types of graphene oxide nanoparticles
alter the morphology of α-syn fibrils, disrupting their interfilament assembly and the resulting aggregates
therefore consist of single protofilaments. Our results further show that graphene oxide sheets reduce the
aggregation rate of α-syn primarily by sequestering of monomers, thereby preventing primary nucleation
and elongation. Graphene quantum dots, on the other hand, interact less avidly with both monomers and
fibrils. Their aggregation inhibitory effect is primarily related to adsorption of aggregated species and
reduction of secondary processes, and they can thus not fully prevent aggregation. This fine-tuned and
differential effect of graphene nanoparticles on amyloid formation shows that rational design of these
nanomaterials has great potential in engineering materials that interact with specific molecular events in
the amyloid fibril formation process. The findings also provide new insight into the molecular interplay
between amyloidogenic proteins and graphene-based nanomaterials in general, and opens up their
potential use as agents to manipulate fibril formation.
Introduction
Multiple age-related human disorders, including Parkinson’s
and Alzheimer’s disease are pathologically associated with the
self-assembly of disease-specific proteins into highly stable
and β-sheet rich amyloid fibrils.1,2 Strategies to modulate or
interfere with the amyloid formation processes guided by an
increasingly detailed understanding of the underlying aggrega-
tion mechanisms is therefore an important step towards the
development of new treatments.3,4
Parkinson’s disease (PD), is a neurodegenerative disease
characterised by degeneration of dopaminergic neurons,
leading to muscle rigidity, bradykinesia and resting tremor,
followed by cognitive impairment at the later stages of the
disease.5 A main pathological hallmark of PD is the accumu-
lation of Lewy bodies in dopaminergic neurons. Lewy bodies
are intracellular inclusions containing amyloid fibrils formed
by α-synuclein (α-syn), a 140-residue presynaptic protein.6,7
α-syn, while being highly stable in its monomeric form under
physiological pH conditions in vitro, readily self-assembles
into amyloid fibrils if destabilised by for example low pH,8
orbital shaking,9 air–water interfaces,10 or destabilising mis-
sense mutations.11 Amyloid fibrils of α-syn, as well as of other
amyloidogenic proteins, form by self-polymerization reactions
that involve primary as well as secondary nucleation reactions
together with fibril elongation (monomer addition to fibril
ends).12 This results in the formation of mature fibrils, but
also in the generation of intermediate species, so-called oligo-
mers, which are often cytotoxic13 and with exposed hydro-
phobic regions.14 The aggregation of α-syn and other amyloi-
dogenic proteins can be inhibited by a wide range of biological
and pharmacological modifiers, including small molecules,15–17
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lipid membranes,18,19 functional polymers,20 peptides,21
protein chaperones,22,23 and antibodies.24,25 Aggregation inhi-
bition is indeed one of the most common targets of
Parkinson’s disease-modifying therapies currently in clinical
trials.26 Nanomaterials are being increasingly explored in this
context, and materials such as gold nanoparticles, magnetic
nanoparticles, graphene oxide, graphene quantum dots,
carbon nanotubes, and fullerene have been shown to effec-
tively modulate and suppress fibrillation of proteins such as
amyloid-β, insulin and islet amyloidogenic polypeptide
(IAPP).27–31 However, it is also frequently reported that nano-
particles catalyse protein aggregation,32–34 suggesting that
their presence in the body could contribute to neurotoxicity.35
In some investigations, carbon-based nanomaterials also
appear to promote amyloid fibril formation, indicating protein
specificity as well as fine-tuned importance of the exact physi-
cal properties and chemical modifications resulting from the
synthesis method used; graphene-based materials can for
example vary significantly with respect to size, shape, thick-
ness, and surface charge.29,36 Studies of how amyloid proteins
interact with different nanomaterials in their monomeric
form, as well as during the aggregation process, are therefore
important to mechanistically understand their function and
towards realizing their putative therapeutic potential.
Graphene-based water soluble nanoparticles, including gra-
phene oxide (GO) sheets and graphene quantum dots (GQD)
have received considerable recent attention for their potential
use in various biomedical applications including gene deliv-
ery,37 tumour treatment,38 photodynamic therapy,39 antibac-
terial materials,40 cellular imaging38,41 and biosensing.38 In
addition, they act as effective inhibitors of the in vitro aggrega-
tion of full length and fragmented forms of the Alzheimer-
associated amyloid-β peptide29,42–44 and also the diabetes-
associated human islet amyloid polypeptide.45,46 Two recent
studies have shown that various functionalised graphene
nanoparticles inhibit and disaggregate α-synuclein fibrils,
resulting in the prevention of α-syn pathology in a mouse
model of Parkinson’s disease.47,48 This biophysical study
follows up on these findings and explores, from a kinetic and
mechanistic perspective, the different inhibitory effects of GO
sheets and GQD nanoparticles obtained via direct carboniz-
ation of citric acid. We report that subtle modification of the
surface chemistry and dimensionality of these graphene nano-
materials can tune not only the rate of the protein aggregation
reaction, but also the mechanism by which inhibition occurs
and the structure and morphology of the ensuing aggregates.
The results provide deepened insights into the aggregation
modulatory function of graphene-based nanomaterials that
may be relevant for their future putative therapeutic potential.
Experimental
Synthesis and characterization of Graphene oxide (GO) and
Graphene quantum dot (GQD) nanoparticles
Water-soluble graphene oxide (GO) and graphene quantum
dot (GQD) nanoparticles were prepared via direct carboniz-
ation and polymerization of citric acid (CA, Sigma Aldrich)
through pyrolysis treatment in an inert atmosphere, following
the procedures described by Dong et al.49 Briefly, 1 g of CA was
added into a 5 mL flask and heated to 200 °C. This resulted in
liquidation of the CA and a colour change from transparent to
pale yellow, and then orange within 30 minutes due to the for-
mation of GQDs. Upon keeping the reaction mixture at this
temperature for 2 hours, the orange liquid transformed into a
black solid suggesting the formation of GO. Finally, the GQD
and GO nanoparticles were neutralized with 1 M NaOH (Sigma
Aldrich, St Louis, MO, USA) under stirring and subjected to
1 hour of sonication in an ultrasonic bath. The materials were
stored at room temperature until further characterization and
use. The functional groups of GO and GQD were characterized
by FTIR spectroscopy using a Shimadzu FTIR1650 spectro-
photometer (Shimadzu Corp., Tokyo, Japan) to collect spectra
in the 500–4000 cm−1 range, following sample preparation
in KBr.
α-Synuclein expression and purification
Wild type α-synuclein (α-syn, 14.4 kDa, 140 residues) was
expressed in E. coli and purified as previously described.50
The α-syn-carrying plasmid was transformed into E. coli BL21
(DE3) by the calcium heat-shock method, and protein
expression was induced by IPTG. The bacterial lysate was then
heated at 90 °C for 10 min followed by centrifugation for
30 min at 15 000g. The centrifuged lysate was filtered (Nalgene
rapid-flow filter, 0.2 µm PES membrane; Thermo Fisher
Scientific, Waltham, MA, USA), loaded onto a pre-equilibrated
5 mL HiTrap Q FF anion exchange column (GE Healthcare,
Chicago, IL, USA) and eluted by a linear gradient of 1 M NaCl
in 20 mM Tris-HCl, pH 8.0. Fractions containing α-syn were
combined and concentrated with Ultra-15 Ultracel 10 K cen-
trifugal filter devices (Millipore, Burlington, MA, USA). The
concentrate was injected on to a HiLoad 16/600 Superdex 75
pg column (GE Healthcare, Chicago, IL, USA) and eluted with
20 mM Tris-HCl buffer, pH 7.4. Fractions containing mono-
meric a-syn were identified by a single-band on SDS-PAGE and
a single elution peak in SEC. To calculate protein concen-
trations, the extinction coefficient of 5960 M−1 cm−1 at
280 nm for α-syn was used. Protein samples were snap-frozen
in liquid N2 and stored at −80 °C until use. Prior to each bio-
physical experiment, monomeric α-syn was purified by size
exclusion chromatography to obtain a pure monomer fraction.
This is important to obtain reproducible amyloid formation
kinetics that are free from artefacts due to preformed seeds in
the starting solution.51 For this, α-syn was injected onto a
Superdex 75 GL 10/300 gel filtration column (GH Healthcare,
Uppsala, Sweden), and eluted using 0.8 mL min−1 of a 25 mM
Tris-HCl buffer with 150 mM NaCl, pH 7.5; highly pure and
monomeric α-syn was obtained (Fig. S1†). The protein concen-
tration was determined by integrating the area under the col-
lected peak or by measuring the UV-vis absorption on a CARY
50 UV-Vis absorption spectrometer (Agilent Technologies,
Santa Clara, CA, US), using a quartz cuvette with 10 mm path-
length (Hellma, Mullheim, Germany).
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Thioflavin-T monitored amyloid formation kinetics
SEC-purified α-syn monomers were added to the wells of
96-well black half-area microtiter plates with transparent
bottom (Corning Inc., Corning, NY, USA, #3881) and sup-
plemented with Thioflavin-T (ThT) (Sigma Aldrich, St Louis,
MO, USA) to final concentrations of 50 μM α-syn and 20 μM
ThT, in a 25 mM Tris-HCl buffer (pH 7.5) with 150 mM NaCl.
The total sample volume in each well was 80 µL. A 2 mm glass
bead was added to each well as previously described,52,53 and
the plates were sealed with plastic film (BIO-RAD, Hercules,
CA, USA) to avoid sample evaporation. The effects of GO and
GQD on α-syn aggregation were assayed by addition of
0–200 µg mL−1 of the nanoparticles. All experiments were per-
formed in triplicate and repeated at least three times. ThT
fluorescence was recorded by a Fluostar OPTIMA or Fluostar
OMEGA fluorescence plate reader (BMG Labtech, Ortenberg,
Germany) at 37 °C in 10-minute intervals for up to 166 h
under shaking conditions (300 rpm, 5 min before each read-
out). The ThT fluorescence was read with bottom optics using
a 440 ± 10 nm bandpass filter for excitation and a 490 ± 10 nm
bandpass filter for emission. The resulting kinetic traces were
analysed in terms of lag-time, half-time and maximum slope.
The lag-time was defined as the time at which the fibril
mass fraction (as determined by ThT emission) reached 0.1.
The slope was defined as the slope of a linear equation fitted
to the data between fibril mass fraction 0.3–0.7, and the half-
time was computed by setting y = 0.5 for the same linear
equation.
Fluorescence spectroscopy
Steady-state fluorescence spectra were recorded using a Varian
Eclipse fluorimeter (Agilent Technologies, Santa Clara, CA,
USA) and a quartz micro-cuvette with 60 µL sample volume
and 3 mm path length, (Hellma Analytics, Mullheim,
Germany). Intrinsic α-synuclein fluorescence (emanating from
tyrosines) was measured in the 290–540 nm range upon exci-
tation at 280 nm.
Circular dichroism (CD) spectroscopy
CD spectra were recorded between 190–280 nm on Jasco J-810
CD spectropolarimeter (Jasco, Tokyo, Japan) using a quartz
cell with 1 mm pathlength (Hellma Micro Absorption Cuvettes
Z800015). The scan speed was set to 50 nm min−1 and the
response time was 0.5 seconds. 5 successive spectra were
recorded and averaged by the computer. All spectra were cor-
rected for background contributions by subtracting appropri-
ate buffer blanks. All experiments were performed at room
temperature.
Atomic force microscopy (AFM)
AFM samples were prepared by depositing 10 µL solution onto
freshly cleaved mica, followed by 15 min incubation to allow
fibrils to settle on the surface. The mica surfaces were there-
after rinsed 5 times with triple-distilled Milli-Q water and
dried under a gentle stream of nitrogen gas. Images were
obtained using an NTEGRA Prima (NT-MDT, Moscow, Russia)
setup equipped with a gold-coated single crystal silicon canti-
lever (NT-MDT, NSG01) with a resonance frequency of 150 kHz
in tapping-mode. Images were recorded in 512 × 512 pixels, at
a 0.5 Hz scan rate and then processed using the Gwyddion
software package by polynomial background subtraction fol-
lowed by planar subtraction and adjustment of linear aberra-
tions.54 Individual fibril lengths were measured manually
using Gwyddion. For measuring fibril heights, the height
profile of each fibril was measured perpendicularly to the
fibril axis, and the associated mica background was subtracted
using Gwyddion.
Dynamic light scattering (DLS) and Zeta potential
DLS measurements were carried out on a Zetasizer nano
(Malvern Panalytical Ltd, Malvern, UK) at room temperature
using plastic cuvettes. The zeta potential of GO and GQD
nanoparticles were also measured on the Zetasizer nano at
room temperature at a concentration of 100 µg mL−1.
Results and discussion
Characterization of graphene oxide (GO) and graphene
quantum dot (GQD) nanoparticles
The chemical and physical properties of the GO and GQD
nanoparticles were analysed by a combination of FTIR, UV-Vis
absorption spectroscopy, DLS, and AFM (Fig. 1). The FTIR
spectra in Fig. 1A and B show that both GO and GQD nano-
particles exhibit infra-red absorption from carboxyl (peaks due
to CvO at 1721 cm−1) and hydroxyl groups (O–H stretching
vibrations in a broad band at ∼3500 cm−1 and O–H bending
vibrations at 1419 cm−1), consistent with their solubility in
water.49 The existence of C–H in GQD is confirmed by presence
of an absorption band at 2967 cm−1 (Fig. 1B). Additionally, the
GO nanoparticles show absorption in the C–O stretching
vibration band (1296 cm−1) that are not present in GQD; this
suggests presence of epoxide groups on its surface and is con-
sistent with that complete carbonization of citric acid has
taken place.49 The carbonization of citric acid and formation
of graphite structure were further confirmed by the presence of
a peak of the 002 plane ranging at 2θ from 15 to 40° in X-ray
powder diffraction (XRD) (ESI Fig. S2†). The GQD nano-
particles display characteristic visible light absorption in a
narrow band centred at 359 nm (ref. 49) (Fig. 1D); the exact
position of this band has been suggested to be sensitive to the
size and shape of GQDs.55 The GO nanoparticles, by contrast,
display broad and unspecific absorption (Fig. 1C) in the visible
range, consistent with previous reports.49 Dynamic light scat-
tering (DLS) was used to determine the hydrodynamic dia-
meter of the GO and GQD nanoparticles. The intensity aver-
aged size distributions of GO and GQD (Fig. 1E and F) show
that our synthesis method, followed by sonication, yields
monodisperse nanoparticle preparations with average dia-
meters of 314 ± 50 nm and 65 ± 10 nm for GO and GQD
respectively. It was also confirmed that both GO and GQD
Paper Nanoscale





















































nanoparticles exhibit excitation-dependent photoluminescence
(ESI Fig. S3†) in accord with previous reports.49 The particle
height, as measured by AFM, (Fig. 1G and H) was approxi-
mately 1.5 nm for both particle preparations, which is in agree-
ment with other reports, but likely an overestimation due to
water adlayers between the graphene sheet and the mica
surface.56 The zeta potential of the GO and GQD nanoparticles
was determined to −38 mV and −8 mV respectively, indicating
differences in their surface-exposed functional groups. The
measured zeta potential values agree well with those reported
by others,57 further supporting the synthesis of typical GO and
GQD nanoparticles.
GO and GQD nanoparticles inhibit α-syn fibril formation
Thioflavin T (ThT) assays, in plate reader format, were used to
monitor the kinetics of the aggregation of 50 µM of SEC-puri-
fied monomeric α-syn (ESI Fig. S1†) into amyloid fibrils in
absence and presence of increasing concentrations of GO and
GQD nanoparticles. The resulting kinetic curves, shown with
three technical replicates of each condition overlaid in Fig. 2A
and B, show that both GO and GQD inhibit α-syn aggregation
in a concentration-dependent manner, which for GO appears
to saturate within the assayed range. Consistent with these
observations, the end-point ThT fluorescence is also reduced
in both cases, suggesting that less fibrils are formed, although
both we and others have pointed out that the complex photo-
physics of ThT when bound to amyloid fibrils and the possible
quenching induced by photo-active inhibitors (as used here)
precludes such direct conclusions to be drawn.58–61
Interestingly, we observe that addition of a low (25 µg ml−1)
concentration of GO increases rather than slows down the
aggregation rate of α-syn. This is also reflected in the
decreased aggregation half-time (Fig. 3A). A similar, albeit less
pronounced effect, is observed for GQD (Fig. 2B and 3A). This
points to that the nanoparticle-to-protein ratio sensitively
determines the aggregation modulatory effect of both GO
and GQDs. Although it is known that different types of
nanoparticles can have different aggregation modulatory
effects, such dual behaviour has not been reported; instead
Fig. 1 Physical and chemical characterization of graphene oxide sheets (GO) and graphene quantum dots (GQD). (A and B) FTIR spectrum of (A):
GO, and (B): GQD. (C and D) UV-Vis absorption spectrum of (C): GO, and (DGQD). (E and F) Intensity-weighted DLS size distribution of (E) sonicated
GO particles (1 hour, ultrasonic bath) and (F) GQD particles (G and H) AFM micrographs of (G) GO and (H) GQD. All scale bars are 1 µm.
Fig. 2 Aggregation kinetics of 50 µM α-syn in presence of (A) GO and
(B) GQD nanoparticles monitored by ThT fluorescence. The experiments
were performed in 25 mM Tris-HCl buffer, with 150 mM NaCl at pH 7.4
and 37 °C with shaking at 200 rpm. Each concentration was run in tech-
nical triplicates, the plot shows data from all triplicates.
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previously published work on α-syn fibril formation have
pointed out only the inhibitory function of graphene-based
nanomaterials.47,48
Due to the observation of an aggregation-enhancing effect
at low nanoparticle-to-protein ratios in combination with a sat-
uration effect at high ratios (Fig. 2) it was not possible to
obtain sufficient data in order to globally fit the aggregation
kinetics to rate laws51 in order to quantitatively describe the
inhibitory mechanisms of action. Still, it is meaningful to
discuss the differences between GO and GQD in mechanistic
terms, based on the clearly different effects that these two
nanoparticles have on the shapes of the aggregation curves
(see ESI Fig. S4† for normalized curves). To describe this in
quantitative terms, we computed the half-time, lag-time, and
the maximum slope of all kinetic traces (Fig. 3, see the
Experimental section for details). The data in Fig. 3 show that
whilst GO and GQD have relatively similar concentration-
dependent effects on the aggregation half-times (Fig. 3A), GO
extends the lag time much more than GQD (Fig. 3B) and has a
more significant effect on the maximum slope (Fig. 3C). This
strongly suggests that GO and GQD inhibit α-syn by different
mechanisms. The concentration-dependent extension of lag
time in presence of GO is consistent with significant inhi-
bition of primary nucleation, which appears not to occur in
the case of GQD. Both nanoparticles affect the maximum
slope which indicates inhibition of secondary processes and/or
elongation.12,62 Interestingly, this also emulates observed
effects of GQD nanoparticles on the aggregation of the dia-
betes-related islet amyloid polypeptide.46 The analysis pre-
sented in Fig. 3 furthermore shows that the enhanced aggrega-
tion rate in presence of low concentrations of both GO and
GQD results from a significant increase in the maximum slope
of the aggregation, suggesting acceleration of secondary pro-
cesses rather than primary nucleation.
Since GO, in particular, was able to enhance α-syn aggrega-
tion at low nanoparticle-to-protein ratios whilst inhibiting at
high GO concentrations, we also tested if it was possible to
modulate its effect by addition bovine serum albumin (BSA) to
form a protein corona on the GO nanoparticles.63 BSA was
added at the start of the aggregation experiment, at two
different molar concentrations (15 and 50 μM) to samples with
α-syn alone and α-syn with 200 µg ml−1 of GO nanoparticles
(corresponding to complete inhibition according to the data
shown in Fig. 2A). The resulting kinetic traces (Fig. 4A) show
that BSA had no effect on the GO-mediated inhibition, infer-
ring that the α-syn interaction is stronger than that between
BSA and GO. We also tested to what extent GO and GQD can
modulate an ongoing aggregation reaction, by adding the
nanoparticles at different time points after the start of the
reaction (Fig. 4B and C). Addition of 200 µg mL−1 GO (Fig. 4B)
at any time point abruptly inhibited aggregation as measured
by the immediate halt of ThT fluorescence increase,
suggesting adsorption of monomers and hence significant
reduction of the effective protein concentration in the aggre-
gating solution. GQD particles, on the other hand, have a
slight retarding effect, when added at the beginning of the
exponential growth phase (15 h), but the aggregation thereafter
resumes with a similar rate as before addition, suggesting a
weaker interaction with monomers in this case.
Altogether, our analysis of the effect of GO and GQD on the
aggregation kinetics of α-syn clearly demonstrates concen-
tration-dependent inhibitory effects, consistent with the
growing body of literature on the effect of graphene nano-
particles on amyloid formation in general,42–44 and corro-
borates in particular two recently published studies on inhi-
bition on α-syn aggregation.47,48 Our results furthermore
extends the knowledge of how graphene-based nanomaterials
interact with amyloid proteins by pin-pointing differences in
the aggregation kinetics in presence of GO and GQD, which in
turn infers that they act by different inhibitory mechanisms.
By assaying the aggregation rate of α-syn over a range of nano-
particle concentrations, we also report that graphene-based
materials can, under certain conditions, also enhance
aggregation.
The inhibitory effects of GO and GQD are governed by their
physicochemical properties
In order to better understand how GO and GQD nanoparticles
exert their aggregation inhibitory effects, we used different bio-
physical assays to probe the interactions between the nano-
particles and the monomeric and fibrillar α-syn. First, taking
advantage of the intrinsic fluorescence emanating from the
Fig. 3 Kinetic parameters describing the aggregation data in Fig. 2. (A)
Half-time of aggregation, computed as the time at which the fibril mass
fraction reaches 0.5. (B) Lag-time, computed as the time at which the
fibril mass fraction reaches 0.1. (C) Maximum slope, computed as the
slope of a linear fit between fibril mass fraction 0.3–0.7. All data are
computed from normalised triplicate measurements (Fig. S3†), error
bars represent the standard deviation.
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four tyrosine residues in α-syn and the optical activity of GO
and GQD nanoparticles, we probed monomer interaction by
tyrosine quenching (Fig. 5A and B). A significant concen-
tration-dependent quenching was observed for both GO and
GQD, consistent with reports that GO can act as a universal
quencher of aromatic amino acids via both static mechanisms
and dynamic quenching;64 our results show that the quench-
ing was not of Förster resonance energy transfer type, as no
increase in GO/GQD emission in the ∼400 nm region was
observed after the intrinsic fluorescence from the GO/GQD
nanoparticles had been subtracted (for non-subtracted
spectra, see ESI Fig. S5†). The degree of quenching (and hence
the interaction) of monomeric α-syn with respectively GO and
GQD was analysed using Stern–Volmer type plots as shown in
Fig. 5C, where F0/F represents the ratio of the emission from
α-syn alone (F0) and the emission from α-syn in presence of
nanoparticles (F). The differences in tyrosine fluorescence
quenching between GO and GQD is negligible, except at very
high nanoparticle concentration suggesting that monomers
may interact similarly with the two nanoparticle types. We next
repeated the tyrosine quenching experiment with pre-formed
α-syn fibrils (ESI Fig. S6†), observing substantially stronger
quenching for GO than for GQD (Fig. 5C). This suggests that
fibrillar α-syn adsorbs more effectively on the GO surface, poss-
ibly due to the larger surface area of the GO particles, which
has previously been shown to be an important modulating
parameter in other protein : graphene systems.65,66
We also used DLS to probe the α-syn nanoparticle interaction
in terms of size distribution alterations (Fig. 6). The intrinsic
size distributions GO and GQD are shown in the top panels in
Fig. 6A and B and correspond to the data shown in Fig. 1.
Monomeric α-syn (Fig. 6C and D), has an average hydrodynamic
diameter of 5 ± 2 nm in accord with previously published
results.67 Upon addition of 50 μg mL−1 of GO nanoparticles to
the α-syn monomer solution, the protein monomer peak in the
intensity-weighted distribution completely disappears (Fig. 6E)
whereas the size and monodispersity of the GO nanoparticles
themselves exhibit apparent increase from 314 ± 50 nm to 441 ±
213 nm. This strongly suggests that α-syn monomers adsorb
avidly to the GO surface as part of the aggregation inhibitory
mechanism and is therefore consistent with the primary nuclea-
tion inhibitory effect that we propose for GO.
Fig. 5 (A and B) Tyrosine fluorescence quenching of 50 µM monomeric
α-syn titrated with (A) GO and (B) GQD. The intrinsic emission from the
nanoparticles alone has been subtracted from each spectrum. (C)
Stern–Volmer plots of quenching efficiency of GO and GQD on tyrosine
fluorescence in α-syn monomers and fibrils, computed from the data in
(A and B) and Fig. S5† (for fibrils).
Fig. 4 (A) Aggregation kinetics of 50 µM α-syn in presence of GO and
bovine serum albumin (BSA). (B and C) Inhibition of the aggregation of
50 µM α-syn upon addition of (B) GO and (C). The aggregation kinetics
were monitored by ThT fluorescence and performed in 25 mM Tris-HCl
buffer, with 150 mM NaCl at pH 7.4 and 37 °C with shaking at 200 rpm.
Each sample was run in technical triplicates, the plots show average data
from all triplicates.
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The size increase would, if caused by α-syn alone, result in
multiple protein layers. It is therefore likely that α-syn to some
extent also lead to GO aggregation. For GQD nanoparticles, the
result is different. Upon addition of 50 μg mL−1 GQD, the
α-syn monomer peak remains visible and there is only very
slight size shift or broadening of the GQD peak (Fig. 6F). This
result, as opposed to the tyrosine quenching data (Fig. 5),
suggests that the interaction between monomeric α-syn and
GQD nanoparticles is not as strong as with GO nanoparticles.
The comparatively minor increase in size of GQD upon adsorp-
tion of α-syn furthermore suggests that a more traditional
protein corona is formed.
The DLS experiments were repeated using α-syn samples
that had been pre-incubated with and without 50 µg mL−1 con-
centrations of GO and GQD at 37 °C and 300 rpm shaking for
40 hours to reach approximately the midpoint of the sigmodal
kinetic curves shown in Fig. 2A and B, e.g. the samples should
contain both monomers and fibrils. The intensity weighted
size distribution of the aggregated α-syn sample alone (Fig. 6G
and H) displays three peaks of which the sub-10 nm species
corresponds to the monomer. The ∼100 and >1000 nm reflect
the formation of different fibrillar species. The sample con-
taining 50 µg ml−1 of GO (Fig. 6I), appears with one peak,
corresponding to a hydrodynamic diameter of 690 ± 110 nm,
suggesting that both monomeric and fibrillar species associate
with GO, forming co-aggregates. In the corresponding experi-
ment with GQD (Fig. 6J), the three α-syn specific peaks remain.
Furthermore, there is an overlap in size between the GQD
nanoparticles themselves and the ∼100 nm α-syn peak prevent-
ing any distinction between the two species based on DLS.
Nevertheless, the DLS data support the result in Fig. 5 that
GQD nanoparticles interact less strongly with fibrillar α-syn,
and furthermore suggests that this holds also for monomers.
A possible explanation to the discrepancy between the tyrosine
quenching experiments (indicating similar binding of mono-
meric α-syn go GO and GQD) and the DLS experiments
(showing that all monomeric α-syn is adsorbed to GO, but not
to GQD) is that the quenching capacity of the nanoparticles
has a relatively small “sphere-of-action”. The tyrosine residues
in α-syn reside in the highly acidic C-terminal region which is
unlikely to directly interact with GO and GQD due to electro-
static repulsion. Hence, this loosely associated region may not
be susceptible to tyrosine quenching even if the rest of the
protein is tightly bound to the GO particle.
In any case, GO appears to have a higher protein binding
capacity than GQD, which could be attributed in part to its
physical characteristics, with a larger surface area per particle.
This has previously been demonstrated as an important factor
in amyloid-β aggregation65 and is in line with recent obser-
vations that the physicochemical properties of nanoparticles
can greatly affect its capacity to perturb the aggregation of
α-syn.48
GO and GQD changes the morphology of α-syn fibrils
Circular dichroism (CD) spectroscopy was used to monitor the
secondary structure of aggregated α-syn after 6 days of incu-
bation at 37 °C with shaking at 200 rpm in presence of
different concentrations of GO and GQD (0–200 µg mL−1)
nanoparticles (Fig. 7A and B respectively). The far-UV CD
spectra of aggregated α-syn in absence of any nanoparticles
(black lines in Fig. 7A and B) display negative ellipticity at
218 nm and positive ellipticity at around 200 nm, consistent
with its expected transformation into β-sheet rich amyloid
fibrils upon long term incubation. The magnitude of the CD
signal in both of these bands decreases with increasing con-
centrations of GO (Fig. 7A) or GQD (Fig. 7B) nanoparticles,
suggesting that less fibrils are formed. This observation is con-
sistent with the ThT intensity reductions reported in Fig. 2,
and with observations by Kim et al.68 Furthermore, at the
highest GO concentration, α-syn retains its random coil con-
figuration as shown by the negative ellipticity at 200 nm,
further substantiating the conclusion from Fig. 2A that GO can
completely inhibit α-syn aggregation if added at sufficient con-
centration, but also that monomeric α-syn remains unstruc-
tured when adsorbed to the GO surface.
Fig. 6 Hydrodynamic radii distributions of α-syn (monomers and fibrils)
and GO/GQD solutions measured by dynamic light scattering. (A) GO
nanoparticles, (B) GQD nanoparticles (C and D) α-syn monomers (data
duplicated for easier comparison across figure columns). (E and F) α-syn
monomers in presence of (E) GO and (F) GQD. (G and H) α-syn mixture
of monomers and fibrils obtained after 40 h incubation (data duplicated
for easier comparison across figure columns) (I and J) α-syn mixture of
monomers and fibrils in presence of (I) GO and (J) GQD.
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AFM (Fig. 8) was thereafter used to examine the mor-
phology of α-syn fibrils formed under the same conditions as
those analysed by CD. The images reveal that α-syn alone
assembles into well-defined mature fibrils with typical lengths
of (1620 ± 560 nm) and a height of (9.3 ± 2.7 nm). For α-syn
fibrils formed in presence of low concentrations of GO
(25–50 µg mL−1) we still observed these typical amyloid fibril
morphologies, but with increasing nanoparticle concentration
the fibrils decrease in both length and thickness (Fig. 8B and
C). Notably, formation of oligomers was not observed. In the
presence of 100 µg mL−1 GO nanoparticles, α-syn aggregates
are markedly shorter (462 ± 192 nm) and thinner (4.4 ±
1.1 nm) with a significant curvilinear appearance. The reduced
length could be attributed to particle-induced fibril fragmenta-
tion.69 The halving of fibril thickness on the other hand indi-
cates a change in fibril structure that is consistent with the for-
mation of single filaments rather than the double filaments
observed in recent high resolution structures of fibrils formed
from full-length α-syn.70,71 This, in turn, would explain the cur-
vilinear appearance of fibrils formed in presence of GO and
GQD (Fig. 8), given the reported reduced bending rigidity of
ribbon-like α-syn fibrils.72 The existence of single protofila-
ments is furthermore consistent with a report that GQD may
Fig. 8 (A) AFM images of 50 µM α-synuclein incubated in the presence of 0–200 µg mL−1 of GO and GQD, in 25 mM Tris-HCl, 150 mM NaCl, pH
7.4, 37 °C with shaking at 200 rpm after 120 hours. Each sample was diluted 10-fold so final α-synuclein and buffer concentration was 5 µM and
2.5 µM with 15 µM NaCl respectively. All scale bars show 2 µm. (B and C) Length (B) and height (C) analysis of AFM images of 50 µM α-synuclein
incubated in the presence of 0–150 µg mL−1 of GO and GQD. Images were individually analysed using Gwyddion and ImageJ, at least 20 fibrils were
counted for each image. The error bars represent the standard deviation.
Fig. 7 (A and B) Circular dichroism spectra of 50 µM α-synuclein incu-
bated for 6 days at 200 rpm shaking, 37 °C, in presence of increasing
concentration of (A) GO, and (B) GQD. Both samples show predominant
β-sheet content, which diminishes with increasing nanoparticle
concentration.
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disintegrate α-syn fibrils,47 although we observed no changes
in fibril morphology when 200 µg mL−1 GO was added to pre-
formed α-syn fibrils (ESI Fig. S7†). No fibrils could be observed
at the highest GO concentration (200 µg mL−1) consistent with
the lack of increase in ThT emission (Fig. 2) and the random
coil CD signature of α-syn fibrils formed under this condition
(Fig. 7). For GQD nanoparticles, we find a less pronounced
reduction in length of the α-syn fibrils (possibly related to
reduced shearing by the smaller size GQD particles and hence
a lesser fragmentation effect). The fibrils are, furthermore, still
present at the highest GQD concentration supporting the
notion that GQD-mediated inhibition is incomplete (Fig. 2)
due to limited adsorption of both monomers and fibrils
(Fig. 6). The curvilinear structures observed with GO are not
present, even though the fibrils formed have reduced height.
These structural and morphological differences between the
fibrils formed in presence of GO and GQD demonstrate that
graphene-based materials not only inhibit fibril formation, but
also affect the nature of the assembled structures. This is an
illustrative example of the sensitivity of amyloid fibril for-
mation reactions towards solution conditions, and presence of
surfaces and demonstrates the polymorphic nature of α-syn
amyloid assemblies.
Conclusions
We have used kinetic assays in combination with other bio-
physical experiments to describe the aggregation modulating
effect of two types of graphene nanoparticles on the aggrega-
tion of Parkinson’s disease-related protein α-syn. We show that
both graphene oxide sheets (GO) and graphene quantum dots
(GQD) under most experimental conditions effectively inhibit
α-syn aggregation, but also reveal that aggregation enhancing
effects can be obtained at low nanoparticle-to-protein ratios.
Using fluorescence spectroscopy and DLS, we show that the
inhibitory effect of the nanoparticles arises from interactions
with both α-syn monomers and fibrils. Moreover, both GO and
GQD alters the morphology of α-syn fibrils, promoting the for-
mation of thin assemblies consisting of one single protofila-
ment, which could perturb secondary nucleation as well as
promote fibril disaggregation due to the loss of stabilising
interfilament interactions.
Importantly, our study reveals that GO and GQD inhibit
α-syn aggregation by partially different mechanisms. GO effec-
tively sequesters both α-syn monomers and fibrils onto the
nanoparticle surface. This reduces the lag time and alters the
maximum slope of the aggregation kinetics profile, suggesting
that monomer sequestration importantly slows down primary
nucleation, but also fibril elongation. This conclusion is con-
sistent with the observation that addition of GO can halt α-syn
aggregation at any time-point of the aggregation reaction and
not only when present from start. GQD, on the other hand,
appears to interact less strongly with both α-syn monomers
and fibrils. Our kinetic analysis consequently reveals no effect
on primary nucleation. Instead, GQD appears to mainly reduce
α-syn’s aggregation rate by interfering with secondary pro-
cesses, thus affecting only the slope of the kinetic profile.
Consequently, we also show that GQD is incapable of halting
α-syn aggregation once the reaction has started.
The interactions between α-syn and the GO and GQD nano-
particles are likely mediated by electrostatic interactions
between the positive charge clusters in the N-terminal region
of α-syn and the negatively charged carboxyl groups on the
surface of GO and GQD, leaving the acidic α-syn C-terminus
solvent exposed, akin to how α-syn binds acidic lipid mem-
branes,73 but, as evidenced by CD spectroscopy (Fig. 7),
without the induction of α-helical structure. This explains the
lack of a difference in the degree fluorescence quenching of
the C-terminal tyrosines in α-syn monomers in presence of GO
and GQD (Fig. 5), that occur despite their clearly higher
affinity for GO according to DLS (Fig. 6). We show that GO has
a more negative zeta potential than GQD suggesting higher
availability of surface-accessible carboxyl groups allowing for
avid multivalent interactions with α-syn monomers preventing,
more effectively than GQD, their participation in primary
nucleation and fibril elongation.
Altogether, this study shows that graphene oxide nano-
particles are potent materials for interfering with α-syn
amyloid fibril formation, and highlights how their inhibitory
mechanisms can be fine-tuned by their morphological and
chemical properties. This contributes to the molecular under-
standing of how nanomaterials may be rationally designed
and potentially used to combat Parkinson’s disease and other
protein aggregation disorders.
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